Core Viewpoint - The company Baolingbao (002286) is currently facing challenges in the market, with its stock price at 12.55 yuan, down 2.03%, and significant trading activity noted on July 3, 2025 [1] Group 1: Company Developments - The company clarified that its DHA algal oil production does not strictly fall under the definition of marine economy as outlined in the national marine economic development plan [1] - Baolingbao's product, Alotose, has not yet been approved for sale in the domestic market, and the approval timeline for its enzyme preparation remains uncertain [1] - The company has submitted an application for the domestic approval of its Alotose enzyme preparation, but it is still pending [1] Group 2: Market Activity - On July 3, 2025, the net outflow of main funds from Baolingbao was 102 million yuan, while speculative funds saw a net inflow of 26.07 million yuan, and retail investors contributed a net inflow of 75.65 million yuan [1]

Core Viewpoint - Selay is redefining the dietary supplement industry with a focus on personalized health solutions, combining natural ingredients with scientific innovation to cater to diverse consumer needs [1][5][7] Group 1: Product Philosophy - Selay emphasizes the importance of pure, natural ingredients sourced from plants and animals, ensuring high quality through rigorous selection processes [3] - The brand utilizes organic materials from local German farms and high-purity fish oil from Norway, achieving an Omega-3 content of 95% with minimal heavy metal residues [3] Group 2: Targeted Product Lines - Selay offers personalized product lines for various demographics, including blood sugar balance capsules for the elderly, hormone-regulating drinks for women, vitality supplements for men, and growth drinks for children [5] - Each product is designed to address specific health needs, such as cardiovascular health, metabolic balance, and developmental support for children [5] Group 3: Consumer Impact - The "Selay Arginine Capsule" exemplifies the brand's approach, combining ingredients like maca, arginine, oyster peptides, and zinc to significantly enhance physical strength and energy levels [7] - Selay aims to provide health solutions that resonate with different lifestyles, from busy professionals to health-conscious homemakers, ensuring that everyone can find their ideal health answer [7] Group 4: Future Outlook - The company is committed to ongoing research and innovation, with plans to expand its product line and offer more precise and effective nutritional solutions [7] - Selay envisions a future where health is easily accessible, promoting a lifestyle that harmonizes scientific advancements with natural wellness [7]

公司预计半年报营收与去年同期持平，但利润端将延续一季度盈利趋势， 主要受益于成本下降和费用管控，尤其电商渠道投流费用大幅削减，利 润贡献显著。 各渠道利润率排序为：专卖店 > 省外商超（山姆等）> 零食量贩 ≈ 电 商 > 大宗商品。山姆渠道黑金枣单品月销已达 1,500 万元，若全渠道 铺货，月销有望翻倍至 3,000 万元。 永辉、天虹等商超调整后，推行"胖东来同款"标准品，对公司产品销 售产生积极影响，无需更换包装直接采购公司标品。 DHA 藻油产品于 2025 年二季度在山姆部分门店试销，预计全国铺货后 月销售额可达 2000 万元。另有红枣奶酪组合等 2-3 款新品储备，预计 中秋节期间推出。 公司改变原材料采购策略，由一次性采购全年用量改为按季度或月度小 批量采购，以降低风险。毛利率能及时反映当季采购成本下降，预计三、 四季度毛利率仍有上升空间。 2025 年公司战略核心是保利润，通过严格的费用管控（特别是电商渠 道）和"创收创立产品"清单，实现扭亏为盈，利润考核权重显著提升。 公司坚持"红枣加健康溯源食品"战略，以红枣为核心进行产品研发， 并利用富余产能尝试开发其他品类，如粉面类食品、粥类产品、 ...

Core Viewpoint - Baolingbao achieved significant growth in Q1 2025, with a revenue of 685 million yuan, a year-on-year increase of 24.23%, and a net profit of 50.36 million yuan, up 117.35%, both reaching historical highs for the period [1] Group 1: Financial Performance - The company's comprehensive gross profit margin increased to 13.65%, up 3.67% from the same period last year [1] - The gross profit margin for the three core products (prebiotics, dietary fiber, and sugar-reducing sweeteners) reached 18.36% [1] Group 2: Product Demand and Market Strategy - There is a growing demand for sugar-reducing sweeteners, with the company's revenue from these products increasing by approximately 96% in Q1 [2] - The revenue growth for specific products includes erythritol (up 123%), allulose (up 82%), and crystalline fructose (up 80%) [2] Group 3: Project Development and Innovation - The production lines for DHA algae oil, lactulose, and HMOs have been completed and are in trial production [2] - The company has initiated the expansion project for allulose and is actively advancing the approval process for HMOs and allulose [2] - In Q1 2025, the company received three invention patent authorizations and participated in multiple industry standard formulations [2] Group 4: Market Outlook and Strategic Focus - The health food market is expected to enter a golden development period, with increasing consumer demand for functional ingredients like prebiotics and dietary fiber [2] - The company aims to leverage its technological advantages and market position to optimize product structure and innovate, adopting a "small, fine, and agile" model to meet differentiated demands [2] - Baolingbao plans to expand its domestic and international markets by utilizing its global layout and brand strength [2]

仙乐健康高度重视研发工作。2025年第一季度公司宣布成立抗衰研究院，开启健康与衰老科学的前沿研 究，同时推出多项创新产品，首发推出QUICKFIZZ 闪溶益生菌固体饮料，萃优酪 DHA藻油凝胶糖果荣 获"蓝帽"备案凭证，欧洲事业部新推出XtraGummies 营养软糖系列产品。 本报讯 （记者王镜茹）4月23日晚间，仙乐健康（300791）科技股份有限公司（以下简称"仙乐健康"） 发布2025年一季度报告。报告显示，2025年第一季度公司实现营业收入9.54亿元，同比增长0.28%；实 现归母净利润6864.07万元，同比增长8.90%；实现毛利率33.09%，同比提升2.47个百分点。 业内认为，仙乐健康有望通过充分发挥中国区的优势底盘能力，将成功经验输出至全球市场，从而在全 球范围内占据更大的市场份额。 美洲地区，一季度虽因关税问题导致市场不确定性增加，但公司美洲出口一季度仍实现良好开局，毛利 率同比提升；同时，BestFormulations工厂的核心业务进入扭亏攻坚期，人效和成本显著改善，亦成功 承接了部分原出口美洲订单，新增订单增速显著，储备超过150项拉美区域项目，预计将于下半年逐步 落地。欧洲地 ...